<DOC>
	<DOCNO>NCT02342249</DOCNO>
	<brief_summary>The primary objective study evaluate time resolution influenza symptom adult acute uncomplicated seasonal influenza A follow administration VX-787 , without concomitant oseltamivir .</brief_summary>
	<brief_title>Study Acute Uncomplicated Seasonal Influenza A Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Part A 1 . Willing able comply NP swab procedure 2 . Subject sign date inform consent form ( ICF ) 3 . Presenting clinic symptom suggestive diagnosis acute influenza . Symptoms include oral temperature ≥38°C ( 100.4°F ) within prior 24 hour , least 1 respiratory symptom AND least 1 systemic symptom . 4 . Understand study treatment provide subject Part A free receive treatment consider appropriate physician Part B 1 . Willing able comply study requirement include treatment plan , study restriction , laboratory test , contraceptive guideline , study procedure 2 . Subject sign date ICF 3 . Present clinic symptom suggestive diagnosis acute influenza . Symptoms include documented oral temperature ≥38°C ( 100.4°F ) time screen process , least 1 respiratory symptom AND least 1 systemic symptom , score least `` moderate '' . 4 . The time onset flulike symptoms time anticipated start treatment must ≤48 hour . Onset symptom define first time ( within 1 hour ) subject become aware respiratory systemic symptom compatible flu experience oral temperature ≥38°C ( 100.4°F ) 5 . Positive Rapid Influenza Diagnostic Test influenza type A 6 . Body mass index ( BMI ) 18.0 33.0 kg/m2 , inclusive , total body weight &gt; 50 kg Part B 1 . History illness clinical condition , opinion investigator subject 's general practitioner , might confound result study pose additional risk administer study drug ( ) subject . 2 . Any condition possibly affect drug absorption ( e.g. , gastrectomy , cholecystectomy , gastrointestinal tract surgery , except appendectomy ) . 3 . Immunized ( intranasal inject vaccine ) influenza 6 month study entry . 4 . At Screening , ECG abnormal deem investigator ( ) clinically significant . 5 . For female subject : Pregnant nursing subject female subject childbearing potential unwilling unable use acceptable method contraception outline protocol . 6 . For male subject , unwilling comply contraception requirement outline study protocol . 7 . Blood donation ( approximately 1 pint [ 500 mL ] ) within 56 day first study drug dose . 8 . Use following medication : Influenza antiviral medication ( oseltamivir , zanamivir , rimantidine , amantadine ) within 14 day ribavirin within 6 month screen . Substrates OATP1B1 and/or OATP1B3 , include atrasentan , bosentan , ezetimibe , glyburide , irinotecan , repaglinide , rifampin , telmisartan , valsartan , olmesartan , Day 1 last dose study drug . `` Statins '' ( i.e. , HMG CoA reductase inhibitor ) may continue , subject caution observed potential `` statin '' relate toxicity . Alternatively , subject abstain statin duration study drug dosing . Strong inhibitor inducer CYP3A metabolism , include carbamazepine , clarithromycin , HIV HCV protease inhibitor , itraconazole , ketoconazole , nefazodone , phenytoin , posaconazole , rifampin , St. John 's wort , telithromycin , voriconazole 2 week prior first dose study drug last PK sample collect Day 8 . An investigational drug device 30 day first dose study drug , 5 half life first dose study drug , time determine local requirement , whichever long . 9 . History excessive alcohol consumption . 10 . History known current usage drug abuse . 11 . Hospitalized subject subject bacterial infection require systemic antibacterial agent time screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Influenza A</keyword>
</DOC>